List view / Grid view
Will gain access to ozureprubart, a potential best-in-class antibody for…
Will gain access to ozureprubart, a potential best-in-class antibody for food allergies, and expand its respiratory, immunology and inflammation pipeline.
The unique mechanism of action of efimosfermin supports its potential…
The unique mechanism of action of efimosfermin supports its potential as a new standard-of-care in liver disease.
The drug is the first in a new class of…
The drug is the first in a new class of oral antibiotics for uncomplicated urinary tract infections in nearly three decades.
The new acquisition by GSK could enable major advancement in…
The new acquisition by GSK could enable major advancement in the standard of care for gastrointestinal stromal tumours (GIST) after nearly two decades.
![The GlaxoSmithKline headquarters building in Brentford, west London, June 2018 [Credit: Willy Barton / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/GSK-3-300x278.jpg)
![The GlaxoSmithKline headquarters building in Brentford, west London, June 2018 [Credit: Willy Barton / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/GSK-3-e1624534468322.jpg)
Tony Wood will assume accountability for R&D across GSK’s portfolio…
Tony Wood will assume accountability for R&D across GSK’s portfolio and pipeline from Dr Hal Barron on 1 August 2022.
